{'fraction_non_alphanumeric': 0.01949317738791423, 'fraction_numerical': 0.003898635477582846, 'mean_word_length': 5.113095238095238, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Efficacy of ceruloplasmin in patients with asthma].

AIM
To evaluate the efficacy ceruloplasmin (Cp) used in the combination therapy of patients with an asthma exacerbation.


SUBJECTS AND METHODS
The trial included 37 asthmatic patients. Chemiluminescence (ChL) registration was used to study the production of reactive oxygen species (ROS) in the patients' blood. Nineteen patients with asthma received conventional treatment. Cp was used as part of combination therapy in 18 asthmatic patients.


RESULTS
ChL intensity was increased the blood of patients with an asthma exacerbation. Cp treatment resulted in a reduction in the generation of ROS in the blood and contributed to positive changes in the clinical symptoms of asthma. In the patients receiving conventional therapy, the high ChL intensity of blood was retained and the clinical symptoms of the disease reduced.


CONCLUSION
The use of Cp in patients with an asthma exacerbation corrects free radical oxidation processes and enhances therapeutic effectiveness.